Novavax | NVAX - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Adma Biologics USD 477.32M 46.13M 2025-12
Agenus USD -271.11M 3.03M 2025-12
AstraZeneca USD 48.67B 2.78B 2025-12
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Cassava Sciences USD 74.4M 7.16M 2025-12
Geron USD 225.87M 22.83M 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
MannKind USD -51.02M 6.47M 2025-12
Merck USD 51.85B 2.79B 2025-09
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 8.65B 680M 2025-12
Novartis USD 46.13B 1.8B 2025-12
Novavax USD -127.75M 28.92M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Sanofi EUR 71.71B 1.55B 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
TG Therapeutics USD 648.02M 40.8M 2025-12